Loading...

Home
Stock
IMUX

IMUX News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

IMUX News

Immunic, Inc. Engages in Medical Conferences

3d agoPRnewswire

Immunic, Inc. Participates in Key Medical Conferences

3d agoNewsfilter

Immunic Regains Nasdaq Compliance with Minimum Bid Price

Apr 01 2026seekingalpha

Immunic Regains Nasdaq Compliance, Shares Rise

Apr 01 2026stocktwits

Immunic Regains Nasdaq Compliance with Minimum Bid Price

Apr 01 2026PRnewswire

Immunic Regains Nasdaq Compliance with Minimum Bid Price

Apr 01 2026Newsfilter

Immunic Appoints Biopharmaceutical Expert Jon Congleton to Board

Mar 31 2026PRnewswire

Immunic Appoints New Board Member with Extensive Biopharmaceutical Experience

Mar 31 2026Newsfilter

IMUX Events

Immunic Files to Sell 458.15M Shares of Common Stock

Immunic files to sell 458.15M shares of common stock for holders

Immunic Appoints Jon Congleton to Board of Directors

Immunic (IMUX) announced the appointment of Jon Congleton to its board of directors, effective March 27. Congleton currently serves as CEO and member of the board of directors of Mineralys Therapeutics (MLYS)

IMUX Monitor News

Immunic Secures $400 Million Financing for Clinical Trials

IMUX Earnings Analysis

No Data

No Data

People Also Watch